Rigel Pharmaceuticals Inc (RIGL) — Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

Rigel Pharmaceuticals Inc (RIGL) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($21.98 Million) in capital expenditures ($12.00K). Check RIGL tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$21.98 Million
USD

Capital Expenditures

$12.00K
USD

Data as of

Dec 2025
Most recent filing

Rigel Pharmaceuticals Inc Capital Reinvestment Ratio (2010–2024)

This chart tracks Rigel Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Rigel Pharmaceuticals Inc.

Annual Capital Reinvestment Ratio for Rigel Pharmaceuticals Inc (2010–2024)

Year-by-year Capital Reinvestment Ratio for Rigel Pharmaceuticals Inc from 2010 to 2024. See RIGL FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.01x $31.47 Million $396.00K ▼ -88.2%
2021 0.11x $5.88 Million $627.00K ▲ +40.1%
2010 0.08x $46.74 Million $3.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow